Early Development & Drug Safety (EDDS)

P-040 - PHARMACOKINETICS, SAFETY AND TOLERABILITY OF VALBENAZINE AFTER THE SINGLE AND MULTIPLE ORAL ADMINISTRATION IN HEALTHY KOREAN MALE SUBJECTS.

P-041 - SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE INTRAVENOUS ADMINISTRATIONS OF SODIUM TAURODEOXYCHOLATE (HY209), A NOVEL CANDIDATE FOR SEPSIS TREATMENT.

P-074 - A PHASE 1 MASS BALANCE STUDY OF FIRSOCOSTAT, A LIVER-TARGETED ACETYL-COA CARBOXYLASE INHIBITOR.

P-162 - INNOVATIVE PHASE-1 STUDY DESIGN IN HEALTHY PARTICIPANTS TO ENABLE RAPID PROGRESSION OF A FIRST-IN-CLASS ORAL PROTEASE INHIBITOR PF-07321332 TO PIVOTAL TRIALS IN COVID-19 PATIENTS.

P-166 - MODEL-BASED ANALYSES OF PRECLINICAL TELEMETRY DATA IN SUPPORT OF DECISION-MAKING IN EARLY DRUG DEVELOPMENT: AN EXEMPLAR WORKFLOW.

P-194 - EFFECTS OF MEAL TYPE ON THE BIOAVAILABILITY OF HSG4112, A SYNTHETIC GLABRIDIN DERIVATIVE, IN HEALTHY SUBJECTS.

PW-023 - DEVELOPING A NOVEL ALGORITHM TO PREDICT NON-ALCOHOLIC FATTY LIVER DISEASE IN VOLUNTEERS UNDERGOING CLINICAL TRIALS.